STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks. U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning.
- ▪You can reach Andrew confidentially on Signal at drewqjoseph.71.
- ▪LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.
- ▪U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning.
Opening excerpt (first ~120 words) tap to expand
STAT PlusBiotech Abivax seeks to ease safety concerns with new data, boosting shares The company released additional strong efficacy results, in a group of hard-to-treat patients Manage alerts for this article Email this article Share this article A micrograph of ulcerative colitis.Wikimedia Commons By Andrew JosephJune 30, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT News.
Discussion
0 commentsMore from STAT News
